Supernus Pharmaceuticals, Inc.
SUPN
$32.15
$0.451.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.82% | 8.94% | 6.79% | -0.61% | -10.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.82% | 8.94% | 6.79% | -0.61% | -10.64% |
| Cost of Revenue | 0.96% | -7.01% | -17.99% | -21.34% | -17.38% |
| Gross Profit | 13.42% | 11.49% | 10.91% | 2.98% | -9.55% |
| SG&A Expenses | 1.73% | -0.32% | 1.79% | -6.21% | -9.42% |
| Depreciation & Amortization | -5.97% | -5.35% | -1.48% | 1.40% | 0.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.89% | 0.98% | 1.11% | -4.36% | -4.86% |
| Operating Income | 950.62% | 361.51% | 132.63% | 130.56% | -87.90% |
| Income Before Tax | 1,628.66% | 3,434.49% | 96.32% | 40.77% | -110.91% |
| Income Tax Expenses | 214.45% | 1,552.10% | 13.00% | 292.02% | 217.40% |
| Earnings from Continuing Operations | 499.24% | 5,512.84% | 133.05% | -87.91% | -129.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 499.24% | 5,512.84% | 133.05% | -87.91% | -129.80% |
| EBIT | 950.62% | 361.51% | 132.63% | 130.56% | -87.90% |
| EBITDA | 53.54% | 44.79% | 30.94% | 23.69% | -30.97% |
| EPS Basic | 496.09% | 5,171.26% | 128.26% | -88.33% | -129.51% |
| Normalized Basic EPS | 472.96% | 260.25% | 120.97% | 113.01% | -75.03% |
| EPS Diluted | 478.63% | 14,025.26% | 168.90% | -87.91% | -133.17% |
| Normalized Diluted EPS | 474.02% | 275.60% | 157.95% | 168.81% | -71.85% |
| Average Basic Shares Outstanding | 1.33% | 1.03% | 0.91% | 1.04% | 1.33% |
| Average Diluted Shares Outstanding | 1.83% | -1.34% | -4.70% | -5.48% | -8.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |